EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients

Zhengyu Zou iD, Zhun Lin, Chenglin Wu, Jizhou Tan, Jie Zhang, Yanwen Peng, Kunsong Zhang, Jiaping Li, Minhao Wu iD, Yuanqing Zhang iD

Advanced Science · 2023-09 · 10 (27)

DOI: 10.1002/advs.202302640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 23.07.2023. Verfasst von Zhengyu Zou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Mesenchymal Stem Cells. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Projects in Guangzhou, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Patient‐derived organoid (PDO) has great potential in precision oncology, but low success rate, time‐consuming culture, and lack of tumor microenvironment (TME) limit its application. Mesenchymal stromal cells (MSC) accumulate in primary site to support tumor growth and recruit immune cells to form TME. Here, MSC and peripheral blood mononuclear cells (PBMC) coculture is used to construct HCC organoid‐on‐a‐chip mimicking original TME and provide a high‐throughput drug‐screening platform to predict outcomes of anti‐HCC immunotherapies. HCC‐PDOs and PBMC are co‐cultured with MSC and Cancer‐associated fibroblasts (CAF). MSC increases success rate of biopsy‐derived PDO culture, accelerates PDO growth, and promotes monocyte survival and differentiation into tumor‐associated macrophages. A multi‐layer microfluidic chip is designed to achieve high‐throughput co‐culture for drug screening. Compared to conventional PDOs, MSC‐PDO‐PBMC and CAF‐PDO‐PBMC models show comparable responses to chemotherapeutic or targeted anti‐tumor drugs but more precise prediction potential in assessing patients’ responses to anti‐PD‐L1 drugs. Moreover, this microfluidic platform shortens PDO growth time and improves dimensional uniformity of organoids. In conclusion, the study successfully constructs microengineered organoid‐on‐a‐chip to mimic TME for high‐throughput drug screening, providing novel platform to predict immunotherapy response of HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMesenchymal Stem CellsHumansLeukocytes, MononuclearPrecision MedicineOrganoidsImmunotherapyLab-On-A-Chip DevicesTumor Microenvironment

Stichwörter der Autor:innen

cancer immunotherapydrug screeningmesenchymal stromal cellsmicrofluidicstumor organoids

Autor:innen und Institutionen

  • Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
  • The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510635, China.

ORCID-Profile: Zhengyu Zou, Minhao Wu, Yuanqing Zhang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Projects in Guangzhou
  • Natural Science Foundation of Guangdong Province
  • China Postdoctoral Science Foundation
  • Fundamental Research Funds for the Central Universities
  • 111 Project
  • Higher Education Discipline Innovation Project

Zitieren

APA

Zou, Z., Lin, Z., Wu, C., Tan, J., Zhang, J., Peng, Y., Zhang, K., Li, J., Wu, M., & Zhang, Y. (2023). Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. Advanced Science, 10(27). https://doi.org/10.1002/advs.202302640

Vancouver

Zou Z, Lin Z, Wu C, Tan J, Zhang J, Peng Y, et al. Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. Advanced Science. 2023;10(27). doi:10.1002/advs.202302640

BibTeX
@article{Zou2023,
  author = {Zou, Zhengyu and Lin, Zhun and Wu, Chenglin and Tan, Jizhou and Zhang, Jie and Peng, Yanwen and Zhang, Kunsong and Li, Jiaping and Wu, Minhao and Zhang, Yuanqing},
  title = {Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {27},
  doi = {10.1002/advs.202302640}
}
Kostenlos starten →